Led · Seed · Jul 2026

Nous develops proprietary extraction technology to create science-backed botanical functional ingredients with a focus on natural alternatives for the energy category. Its flagship branded ingredient, Koncentra, is designed to support energy, focus and mood and is advancing through clinical research and commercial partnerships. The company is expanding into international markets and has an established partnership with dsm-firmenich. Nous plans to commission additional clinical studies and broaden its supply chain across Europe and Asia as it commercialises Koncentra. It is also developing additional functional ingredients on its extraction platform and expanding its team with key hires to support international growth.

Participated · Equity · May 2026

P2 Science develops proprietary, nature-inspired chemical processes to produce renewable specialty ingredients with a focus on performance and sustainability at scale. The company has launched beauty ingredients including Citrolatum® P, a 1:1 plant-based petrolatum replacement, and CitroComplex® Nourish, a natural oil blend for skin and hair, and entered a strategic partnership with Algenesis to develop 100% biobased, biodegradable polyurethanes. P2 has been recognized by Fast Company in 2025 and 2026 and was selected for L'Oréal's L'AcceleratOR sustainable innovation accelerator. It recently received $2.8 million in non-dilutive ARPA-E funding to accelerate catalyst innovation via AI-enhanced autonomous labs. The company plans to use its new equity financing to scale commercial production in beauty and expand its platform into adjacent markets such as aroma technologies, performance polymers, home care, coatings, and crop care. P2 was co-founded by Professor Paul Anastas and Dr. Patrick Foley at Yale's Center for Green Chemistry and Green Engineering and is based in Woodbridge, Connecticut.

Participated · Seed · Apr 2026

Cosaic develops a new category of food ingredients using yeast fermentation to provide creaminess, stability and functional performance in one ingredient, aiming to reduce reliance on multiple components and additives. The company positions its platform to help food and beverage manufacturers address formulation trade-offs between clean label, sensory performance, and cost. Cosaic employs 15 people and is in a pre-Series A stage, preparing for U.S. market entry next year. Its recent partnership with Ingredion and strategic investment from dsm-firmenich Ventures serve as commercial and strategic validation. The startup plans to use recent funding to complete regulatory work, scale production, and run industrial trials with large clients as it moves toward launch readiness.

Participated · Equity · Feb 2026

ATRO Medical is a Netherlands-based clinical-stage orthopedic medical device company focused on addressing post-meniscectomy pain syndrome with its flagship Artimis Meniscus Prosthesis. The implant is designed to restore joint biomechanics, alleviate pain, and delay osteoarthritis progression for patients who have undergone meniscus removal. The company has reached a key clinical milestone with its latest prosthesis design and is currently conducting ongoing studies in affected patients. Recent activities include strengthening its intellectual-property portfolio and joining the PlugAndPlay Health incubator in the United States, broadening its international exposure. To support upcoming pivotal trials in both the U.S. and Europe, ATRO Medical is optimizing manufacturing, regulatory readiness, and clinical operations. A new leadership structure features Maarten van der Zanden as CEO, Anita Brinks as COO, and founder Tony van Tienen as Chief Medical Officer. The firm also plans to open a share funding campaign on the Eyevestor platform to allow patient and private-investor participation in its next development stage.

Participated · Series A · Jan 2026

Octarine Bio engineers microbial systems via precision fermentation to create PurePalette, a natural pigment platform that can deliver the full colour spectrum through a single production process. The pigments are designed to integrate seamlessly with existing textile dyeing workflows while offering superior colour strength, performance and stability compared with fossil-based dyes. Beyond textiles, the company is exploring applications in food & beverage and cosmetics, emphasising a significantly lower environmental footprint across sectors. With the latest capital, Octarine will scale industrial-level production of its first three flagship colours and execute commercial partnerships already in place. The firm also plans to validate PurePalette at industrial scale and broaden product development into additional industries. Including the new funding, Octarine’s Series A totals €12.8 million, reflecting continued investor confidence. Key backers now include The Footprint Firm, Edaphon, Unconventional Ventures, DSM-Firmenich Ventures, Oskare Capital, several business angels, and noted Danish biotech veterans Per Falholt and Steen Riisgaard.